Suppr超能文献

血管加压素在血管舒张性休克和脓毒性休克中的应用

Vasopressin in vasodilatory and septic shock.

作者信息

Russell James A

机构信息

Division of Critical Care Medicine, University Of British Columbia, Vancouver. British Columbia, Canada.

出版信息

Curr Opin Crit Care. 2007 Aug;13(4):383-91. doi: 10.1097/MCC.0b013e328263885e.

Abstract

PURPOSE OF REVIEW

The aim of this article is to review mechanisms of action of vasopressin and clinical studies of vasopressin in septic shock.

RECENT FINDINGS

Arginine vasopressin is an important stress hormone that has both vasoactive and antidiuretic properties. The vasoactive properties of vasopressin have been more applicable clinically because of the discovery by Landry and colleagues that there is a deficiency of vasopressin in septic shock and that infusion of relatively low doses of vasopressin improves responsiveness to infused catecholamines (such as norepinephrine). There are at least 16 clinical studies of infusion of vasopressin in patients who have septic shock. The majority of studies found that vasopressin infusion increased blood pressure and urine output, and decreased the dose requirement of norepinephrine. Several studies showed that vasopressin infusion increased urine output. Both vasopressin and norepinephrine have important adverse effects including decreased cardiac output, decreased heart rate, arrhythmias, myocardial ischemia, mesenteric ischemia, and digital ischemia.

SUMMARY

It is still unclear whether there is net benefit from low dose vasopressin infusion in patients who have septic shock. There may be certain patients who benefit but there are few studies of a prolonged vasopressin infusion to determine which patients benefit.

摘要

综述目的

本文旨在综述血管加压素的作用机制以及血管加压素在感染性休克中的临床研究。

最新发现

精氨酸血管加压素是一种重要的应激激素,具有血管活性和抗利尿特性。由于兰德里及其同事发现感染性休克患者存在血管加压素缺乏,且输注相对低剂量的血管加压素可改善对输注儿茶酚胺(如去甲肾上腺素)的反应性,血管加压素的血管活性特性在临床上得到了更广泛的应用。至少有16项关于在感染性休克患者中输注血管加压素的临床研究。大多数研究发现,输注血管加压素可提高血压和尿量,并降低去甲肾上腺素的剂量需求。几项研究表明,输注血管加压素可增加尿量。血管加压素和去甲肾上腺素都有重要的不良反应,包括心输出量减少、心率减慢、心律失常、心肌缺血、肠系膜缺血和指端缺血。

总结

对于感染性休克患者,低剂量输注血管加压素是否有净获益仍不清楚。可能有某些患者会从中获益,但很少有关于长期输注血管加压素以确定哪些患者获益的研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验